Gab 2 Inhibitors

AGI-6780 is a selective Gab 2 inhibitor that hinders its phosphorylation and subsequent activation. By targeting the phosphorylation sites on Gab 2, AGI-6780 disrupts the recruitment of downstream effectors and modulates cellular responses influenced by Gab 2 signaling. This direct inhibition specifically interferes with the phosphorylation-dependent functions of Gab 2, providing a targeted approach to modulate its activity.

GNF-5837 is a compound that indirectly inhibits Gab 2 by targeting the upstream receptor tyrosine kinase (RTK) signaling. By blocking RTK activation, GNF-5837 disrupts the initiation of Gab 2-mediated signaling cascades, indirectly modulating Gab 2 function. This indirect inhibition occurs through the interference with the RTK-dependent activation of Gab 2, affecting its downstream signaling and cellular responses.

Dasatinib indirectly inhibits Gab 2 by targeting multiple tyrosine kinases, including Src family kinases. By inhibiting these kinases, Dasatinib disrupts the activation of Gab 2 and downstream signaling events, indirectly modulating Gab 2 function. This indirect inhibition occurs through the interference with the broad spectrum of tyrosine kinases that contribute to Gab 2 activation and its subsequent cellular responses.

AZD8055 indirectly inhibits Gab 2 by targeting the mTOR signaling pathway. By inhibiting mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), AZD2014 disrupts the downstream signaling cascades involving Gab 2, indirectly modulating its function. This indirect modulation occurs through the interference with the mTOR-dependent regulation of Gab 2, affecting its activation and the subsequent cellular responses influenced by Gab 2 signaling.

PI-103 indirectly inhibits Gab 2 by targeting the PI3K/Akt signaling pathway. By inhibiting both PI3K and mTOR, PI-103 disrupts the downstream signaling events involving Gab 2, indirectly influencing its function. This indirect inhibition occurs through the interference with the PI3K/Akt pathway, which is intricately linked to Gab 2 activation and its subsequent cellular responses.

PP2 is a selective Src family kinase inhibitor that indirectly modulates Gab 2 by affecting upstream tyrosine kinase signaling. By inhibiting Src family kinases, PP2 disrupts the activation of Gab 2 and downstream signaling events, indirectly influencing Gab 2-mediated cellular responses. This indirect modulation occurs through the interference with the specific tyrosine kinases involved in Gab 2 activation and its subsequent cellular responses.

Ruxolitinib indirectly inhibits Gab 2 by targeting the JAK/STAT signaling pathway. By inhibiting JAK1 and JAK2, Ruxolitinib disrupts the downstream signaling events involving Gab 2, indirectly modulating its function. This indirect inhibition occurs through the interference with the JAK-dependent regulation of Gab 2, affecting its activation and the subsequent cellular responses influenced by Gab 2 signaling.

Saracatinib indirectly inhibits Gab 2 by targeting Src family kinases. By inhibiting these kinases, Saracatinib disrupts the activation of Gab 2 and downstream signaling events, indirectly influencing Gab 2-mediated cellular responses. This indirect modulation occurs through the interference with the specific Src family kinases involved in Gab 2 activation and its subsequent cellular responses.

17-DMAG is a heat shock protein 90 (Hsp90) inhibitor that indirectly modulates Gab 2 by affecting protein folding and stability. By inhibiting Hsp90, 17-DMAG disrupts the stability of proteins involved in Gab 2 signaling, indirectly influencing Gab 2 function.

SB203580 indirectly inhibits Gab 2 by targeting the p38 MAPK signaling pathway. By inhibiting p38 MAPK, SB203580 disrupts the downstream signaling cascades involving Gab 2, indirectly modulating its function. This indirect modulation occurs through the interference with the p38 MAPK-dependent regulation of Gab 2, affecting its activation and the subsequent cellular responses influenced by Gab 2 signaling.